您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Tofacitinib
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tofacitinib
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Tofacitinib图片
CAS NO:477600-75-2
包装:5mg, 10mg, 50mg, 100mg
包装与价格:
包装价格(元)
Free Sample (0.5-1 mg)电议
10mM*1mL in DMSO电议
5mg电议
10mg电议
50mg电议
100mg电议

产品名称
CP-690550, Tasocitinib
产品介绍

生物活性

Tofacitinib (CP-690550,Tasocitinib)是一种新型JAK3抑制剂,IC50为1 nM,作用于JAK2和JAK1选择性低20到100倍。CP-690550 是特定的口服JAK3抑制剂, 作用于JAK2 和 JAK1,效果分别低20和100倍。CP-690550 对30种其他激酶没有作用效果,平均IC50 > 3000 nM。CP-690,550抑制IL-2诱导的增殖,比作用于GM-CSF诱导的增殖效果强30倍。


化学数据

分子量312.37
分子式C16H20N6O
CAS号477600-75-2
纯度100.00%
溶解性(25°C)DMSO ≥60 mg/mL
储存和运输条件-20°C, sealed
常温运输及临时存放

实验操作 来自于公开的文献,仅供相同实验参考(如实验材料、目的不同,请参考其他文献)

细胞实验
细胞系cytokine-dependent NK92 cell line
方法(A) After cytokine starvation for 24 hours, NK92 cells were stimulated by the addition of human IL-2 for 48 hours with and without the addition of serially increasing concentrations of tofacitinib. 3H-thymidine was added during the last 6 hours of the cultures. Cells were then harvested and analyzed for 3H-thymidine incorporation. (B) Cytokine-starved NK92 cells were stimulated with human IL-2, combined IL-6/IL- 6R, or IL-12 for 48 hours with and without serially increasing concentrations of tofacitinib. (C) The NK92 cells were treated as those in panel B with and without a single 50nM dose of tofacitinib. Data are presented as means ±SD (A-C) and are representative of 3 independent experiments. (D) After cytokine starvation for 24 hours, NK92 cells were stimulated with 30 ng/mL of IL-2, 100 ng/mL of combined IL-6/IL-6R, or 100 ng/mL of IL-12 for 1 hour with and without the addition of tofacitinib. The cell lysates were immunoblotted with an anti–phospho-STAT5 monoclonal antibody and an anti-STAT5 antibody. ss-Actin was used as an input control. Data are representative of 3 independent experiments.
浓度0~400 nM
处理时间48 h

动物实验
动物模型IL-15–transgenic CD8 T-cell leukemia–bearing mice
配制dissolved in polyethylene glycol 300 (PEG300; VWR Scientific Products)
剂量50 mg/mL
给药处理continuously administered via a subcutaneous mini-osmotic pump (ALZET)

不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

小鼠大鼠豚鼠仓鼠
重量 (kg)0.020.151.80.40.0810
体表面积 (m2)0.0070.0250.150.050.020.5
Km系数36128520
动物 A (mg/kg) = 动物 B (mg/kg) × 动物 B的Km系数
动物 A的Km系数

例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。


储备液配制

以下数据基于产品分子量,对于特殊产品,请参照COA中的储备液配制条件和说明进行操作。

Concentration / Solvent Volume / Mass1 mg5 mg10 mg
1 mM3.2013 mL16.0067 mL32.0133 mL
5 mM0.6403 mL3.2013 mL6.4027 mL
10 mM0.3201 mL1.6007 mL3.2013 mL